NVO•benzinga•
Novo Nordisk Presented Data From Phase 3 REAL8 Basket Study, Which Showed That Once-weekly Sogroya (Somapacitan) Was Non-inferior To The Once-daily Growth Hormone Norditropin (Somatropin) In Improving Yearly Growth Rate In Children With Growth Disorders
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 12, 2025 by benzinga